Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.
Learn More
Brain tumors are caused by the growth of abnormal cells in the brain. At Alfa Cytology, we are committed to helping our clients unravel the complexity of these diseases by providing integrated preclinical research solutions.
Brain tumors are a large group of heterogeneous tumors that affect the central nervous system and include some of the deadliest cancers. Primary malignant brain tumors remain one of the deadliest cancers, despite a better understanding of their tumorigenic processes and a multimodal approach to treatment in recent years. Brain tumors are also the most common solid tumor in children and are the leading cause of cancer-related morbidity and mortality in this population.
Fig.1 Primary brain tumors and metastatic brain tumors.
The brain tumor diagnosis and treatment market were worth around USD 1,395.7 million in 2021 and is estimated to grow to about USD 2,036.5 million by 2028, with a compound annual growth rate (CAGR) of approximately 6.5 percent over the forecast period.
Promising brain tumor pipeline therapies in various stages of development include:
Sponsors | NCT | Therapeutics | Phase |
M.D. Anderson Cancer Center | NCT01740570 | Cabazitaxel | 123 |
Myrexis Inc. | NCT00393965 | MPC-6827 | 123 |
Rockefeller University | NCT00893945 | DC/AAT | 123 |
ABM Therapeutics Shanghai Company Limited | NCT05892653 | ABM-1310 | 123 |
The blood-brain barrier (BBB) is a major factor contributing to the inefficiency of various therapies for brain tumors. Through innovative approaches such as nanotechnology-based carriers, receptor-mediated delivery systems and focused ultrasound technology, researchers have made significant advances in improving drug delivery to brain tumors and increasing treatment success.
Fig.2 Brain cancer treated with novel nanoparticle (NP) therapy. (Mitusova, K., et al., 2022)
At Alfa Cytology, we are dedicated to providing comprehensive and innovative solutions for all your brain tumor-related needs. Our team of highly skilled professionals, backed by cutting-edge research and state-of-the-art facilities, offers a wide range of services to address the multifaceted aspects of brain tumor management.
We understand the critical role animal models play in advancing brain cancer research. We offer state-of-the-art animal model development services tailored specifically for brain cancer studies, including pharmacokinetics studies and drug safety evaluation.
Meningiomas | Gliomas |
|
|
Ependymomas | Medulloblastomas |
|
|
At Alfa Cytology, we are committed to providing comprehensive and cutting-edge solutions for the management of brain tumors. For more information about our brain tumors research and development initiatives, or to inquire about our comprehensive services, please don't hesitate to contact us.
Reference
For research use only.